Côte d’Ivoire

RISE is a five-year global project funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Agency for International Development (USAID). RISE works with countries to achieve a shared vision of attaining and maintaining epidemic control, with stronger local partners capable of managing and achieving results through sustainable, self-reliant and resilient health systems by 2024. RISE’s contributions to this work will lead to fewer new HIV infections, decreased HIV-related morbidity and mortality, and increased quality of life for people living with HIV. With USAID PEPFAR investments, RISE supports countries to achieve and maintain epidemic control by providing strategic technical assistance and direct service delivery to improve HIV prevention, case finding, treatment programming and viral load suppression. The primary objectives of the RISE project are to: 1) attain and maintain HIV epidemic control among at-risk adult men, women and priority populations; 2) attain and maintain HIV epidemic control among key populations; 3) strengthen health systems including improved program management, health information systems, human resources for health and financial systems to ensure attainment and maintenance of epidemic control; and 4) support the transition of direct funding and implementation to capable local partners to meet the PEPFAR goal of 70% of funding to local partners by 2020. The project is led by Jhpiego with the following partners: ICAP at Columbia University, Management Sciences for Health, Anova, BAO Systems, Johns Hopkins University Center for Public Health and Human Rights and Mann Global Health. RISE is currently active in several countries, including Côte d’Ivoire.

This four-year project, funded by the Bill & Melinda Gates Foundation, builds on the PMA2020 project, which used innovative mobile technology to support low-cost, rapid-turnaround surveys monitoring key health and development indicators. PMA is enhancing this survey platform to generate high-quality data and ensure that governments, donors, managers and advocates use this data to make decisions regarding family planning programs. In addition to scaling up the survey platform for more widespread use, this project supports expanding it to include additional technical areas. Co-led by Jhpiego and the Bill & Melinda Gates Institute for Population and Reproductive Health, this project is operational in several African and Asian countries, including Côte d’Ivoire.

Unitaid is funding a consortium, led by Expertise France, that seeks to eliminate cervical cancer in Burkina Faso, Côte d’Ivoire, Guatemala and the Philippines through secondary prevention (i.e., detecting disease early to slow or halt its progress). The three-year SUCCESS project is designed to shift the countries from a largely opportunistic cervical cancer screening model to a systematic approach centered on innovations related to: 1) reinforced and simplified cervical cancer screening through the introduction of human papilloma virus (HPV) testing with self-collection sampling; 2) secondary prevention of cervical cancer including use of efficient methods for treatment of cervical precancerous lesions such as thermal ablation; and 3) intensified dissemination of information on cervical cancer and new preventive technologies. In so doing, SUCCESS aims to support countries to “leapfrog” to a state-of-the-art services model recommended by the World Health Organization. As the implementing partner of the consortium, Jhpiego is integrating and expanding cervical cancer prevention and treatment services into both new and existing platforms, relying on our established relationships with governments and stakeholders in all four countries. Through demand-generation and community engagement activities, the project plans to screen a total of 185,000 women, a significant proportion of whom will be women living with HIV.

Funded by the Bill & Melinda Gates Foundation, this program promotes access to family planning choices in West African countries by supporting the introduction and scale-up of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC). DMPA-SC is an innovative injectable contraceptive—also known as Sayana® Press—that can dramatically expand access and choice for women. Jhpiego is enhancing ongoing efforts of the Access Collaborative by strengthening health systems to accelerate introduction and scale-up of DMPA-SC in several West African countries, including Côte d’Ivoire.